Haematologica
HAEMATOL/2016/153130
Version 3

Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined Phase I/II results of the EORTC/GIMEMA AML-14A Trial

Dominik Selleslag, Stefan Suciu, Giovanna Meloni, Petra Muus, Constantijn J.M. Halkes, Adriano Venditti, Safaa M. Ramadan, Hans Pruijt, Liv Meert, Marco Vignetti, Jean-Pierre Marie, Sébastian Wittnebel, Theo de Witte, Sergio Amadori, Roelof Willemze, and Frédéric Baron

Disclosures: DS has received speaker honoraria from Genzyme/Sanofi. FB has received speaker honoraria and travel grants from Genzyme/Sanofi. RW has been member of the Scientific Advisory Board of Genzyme/Sanofi concerning clofarabine. The other authors have nothing to disclose with respect to clofarabine.

Contributions: Conception and design: Dominik Selleslag, Stefan Suciu, Petra Muus, Roel Willemze, Sergio Amadori, Theo de Witte, Jean-Pierre Marie. Provision of study materials or patients: Dominik Selleslag, Giovanna Meloni, Petra Muus, Constantijn J.M. Halkes, Adriano Venditti, Hans Pruijt, Jean-Pierre Marie, Sébastian Wittnebel, Theo de Witte, Sergio Amadori, and Roelof Willemze Collection and assembly of data: Dominik Selleslag, Stefan Suciu, Giovanna Meloni, Petra Muus, Constantijn J.M. Halkes, Adriano Venditti, Safaa M Ramadan, Hans Pruijt, Liv Meert, Marco Vignetti, Jean-Pierre Marie, Sébastian Wittnebel, Theo de Witte, Sergio Amadori, Roelof Willemze, and Frédéric Baron